In the battle of the big biotech stocks, how do Gilead and Amgen stack up against each other?
Two of the biggest biotechs have produced quite different
results for shareholders. Amgen's (NASDAQ:AMGN) valuation nearly doubled during
the the last five years, while Gilead Sciences' (NASDAQ:GILD) stock price more
than quadrupled.
Looking only at performance this year is a different story
altogether. Amgen has basically tread water, with shares close to the same
price as at the beginning of 2016. Gilead's stock price, on the other hand, has
dropped by a double-digit percentage year-to-date.
All of that is in the past, though. Which of these big
biotech stocks is the better pick for long-term investors going forward? Let's
see how Gilead and Amgen stack up against each other.
Continue to read at The Motley Fool …